^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD8 expression

    i
    Other names: CD8, CD8A, cluster of differentiation 8, CD8a Molecule, T-Cell Surface Glycoprotein CD8 Alpha Chain, T-Lymphocyte Differentiation Antigen T8/Leu-2, CD8 Antigen, Alpha Polypeptide (P32), Leu2 T-Lymphocyte Antigen, OKT8 T-Cell Antigen, T-Cell Antigen Leu2, T Cell Co-Receptor, T8 T-Cell Antigen, CD8a Antigen
    Entrez ID:
    925
    Related biomarkers:
    Expression
    Others
    4ms
    Dendritic Polylysine with Paclitaxel and Triptolide Codelivery for Enhanced Cancer Ferroptosis through the Accumulation of ROS. (PubMed, ACS Appl Mater Interfaces)
    Furthermore, we determined that ferroptosis may strengthen the immune response by increasing the expression of CD8+ T cells and IFN-γ+ cells while decreasing Treg cells. In general, PTPP may be a potential system for NSCLC treatment.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11)
    |
    CD8 expression
    |
    paclitaxel
    11ms
    Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells. (PubMed, Oncotarget)
    Single cell RNAseq analysis of tumor infiltrating CD8 T cells shows positive correlation of CTLA-4, TIM-3, LAG-3, TIGIT, GITR, 4-1BB, and OX40 with PD-1 but negative correlation of KLRG1 with PD-1. The anti-correlation of PD-1 and KLRG1 expression in human tumor infiltrating CD8 T cells suggests the potential for combination therapy supra-additive benefits of anti-PD-1 and anti-KLRG1 therapies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • KLRG1 (Killer Cell Lectin Like Receptor G1)
    |
    PD-1 expression • CD8 expression
    11ms
    Innovative PBMC-derived humanized mouse model reveals CD8+ T cell-intrinsic regulation during antitumor immunity. (PubMed, Methods)
    This method readily yields over 10 % of human CD45+ cells within the PBMCs of humanized mice with high editing efficiency of gene expression in CD8+ T cells that can be subsequently detected in the tumor microenvironment (TME). Our work provides a new method to generate a PBMC-derived humanized mouse model for investigating regulators of interest during antitumor immunity in a cell type-specific manner.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    |
    CD8 expression
    11ms
    Clinical Study on Safety and Immunogenicity of lyophilized tuberculosis mRNA Vaccine (RH119) in Healthy Adult Subjects (ChiCTR2400094049)
    P=N/A, N=56, Wuhan Jinyintan Hospital (Wuhan Infectious Disease Hospital); Wuhan Jinyintan Hospital (Wuhan Infectious Disease Hospital)
    New trial
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL4 (Interleukin 4)
    |
    CD8 expression • IL2 expression
    11ms
    PRDX2 induces tumor immune evasion by modulating the HDAC3-Galectin-9 axis in lung adenocarcinoma cells. (PubMed, J Transl Med)
    This study reveals the role of the PRDX2/HDAC3/Galectin-9 axis in LUAD immune escape and indicates Galectin-9 as a promising target for immunotherapy.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • GZMB (Granzyme B) • PRDX2 (Peroxiredoxin 2) • PRF1 (Perforin 1) • HDAC3 (Histone Deacetylase 3) • LGALS9 (Galectin 9)
    |
    CD8 expression
    11ms
    Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial. (PubMed, Signal Transduct Target Ther)
    XB2001, a fully human monoclonal antibody neutralizing IL-1α, was evaluated for safety and preliminary efficacy with trifluridine/tipiracil (FTD/TPI) and bevacizumab in metastatic colorectal cancer patients previously treated with oxaliplatin- and irinotecan-based chemotherapies. High intratumoral IL-1α expression at baseline and CD8/PD-L1 infiltration are associated with a better progression-free survival. The combination of XB2001 with FTD/TPI and bevacizumab is feasible and safe, and showed encouraging clinical activity in chemotherapy-resistant mCRC.
    P1 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IL6 (Interleukin 6)
    |
    CD8 expression
    |
    Avastin (bevacizumab) • oxaliplatin • irinotecan • Lonsurf (trifluridine/tipiracil) • Natrunix (vilamakitug)
    11ms
    Metabolically activated and highly polyfunctional intratumoral VISTA+ regulatory B cells are associated with tumor recurrence in early-stage NSCLC. (PubMed, Mol Cancer)
    In NSCLC patients, prediction analysis performed by PENCIL revealed the presence of an association between PSGL-1+CD8+ T cells and VISTA+ Bregs with lung recurrence. Our findings suggest a potential interaction between Bregs and T cells through the VISTA-PSGL-1 axis, that could influence NSCLC recurrence.
    Journal
    |
    CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • CSF2 (Colony stimulating factor 2) • VSIR (V-Set Immunoregulatory Receptor)
    |
    CD8 expression
    11ms
    Single-cell transcriptomics unveils multifaceted immune heterogeneity in early-onset versus late-onset cervical cancer. (PubMed, World J Surg Oncol)
    Regarding cancer-associated fibroblasts (CAFs), EOCC was enriched with inflammatory CAFs, whereas LOCC harbored a higher proportion of antigen-presenting CAFs. These findings reveal the multifaceted immune heterogeneity between EOCC and LOCC, underscoring the imperative for age-tailored immunotherapeutic strategies.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    CD8 expression • CD4 expression
    11ms
    Buparlisib and Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Immunogenomic Biomarkers of Efficacy from the BERIL-1 Study. (PubMed, Target Oncol)
    In this immunogenomic analysis of BERIL-1, improved HRs for OS were seen in patients with tumor immune infiltration and selected oncogenic alterations, including PIK3 and NOTCH pathway activation (NCT01852292).
    Journal • Tumor mutational burden • IO biomarker
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • NOTCH1 (Notch 1) • CD8 (cluster of differentiation 8)
    |
    TP53 mutation • PIK3CA mutation • CD8 expression
    |
    paclitaxel • buparlisib (AN2025)
    11ms
    Acquisition of discrete immune suppressive barriers contributes to the initiation and progression of preinvasive to invasive human lung cancer. (PubMed, bioRxiv)
    The single-cell architecture identifies determinants of early disease emergence and progression, which may be developed not only as diagnostic/prognostic biomarkers but also as targets for disease interception. Additionally, our dataset constitutes a valuable resource for the preinvasive lung cancer research community.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • TREM2 (Triggering Receptor Expressed On Myeloid Cells 2)
    |
    CD8 expression • CXCL13 expression
    11ms
    Activated CD27+PD-1+ CD8 T Cells and CD4 T Regulatory Cells Dominate the Tumor Microenvironment in Refractory Celiac Disease Type II. (PubMed, Gastro Hep Adv)
    Flow cytometry confirmed the presence of the inhibitory receptor NKG2A on expanded duodenal CD8 T cells and HLA-E, the ligand for NKG2A, on expanded aberrant cells. RCDII is characterized by the simultaneous presence of an activated CD27+PD-1+ memory CD8αβ T cell subset and CD4 Tregs, suggesting that checkpoint blockade with anti-NKG2A/PD-1 and/or anticytotoxic T lymphocyte antigen 4 may be an attractive treatment option.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IL2RA (Interleukin 2 receptor, alpha) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule) • IL7R (Interleukin 7 Receptor) • TNFRSF9 (TNF Receptor Superfamily Member 9) • ICOS (Inducible T Cell Costimulator) • CD27 (CD27 Molecule) • HLA-E (Major Histocompatibility Complex, Class I, E) • FOXP3 (Forkhead Box P3) • GZMA (Granzyme A) • IL32 (Interleukin 32) • ITGAE (Integrin Subunit Alpha E) • TNFRSF18 (TNF Receptor Superfamily Member 18) • PRF1 (Perforin 1) • KLRC1 (Killer Cell Lectin Like Receptor C1) • NKG7 (Natural Killer Cell Granule Protein 7)
    |
    CD8 expression
    11ms
    Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction. (PubMed, J Immunother Cancer)
    The signature holds promise for impacting clinical decision-making, pan-cancer patient stratification, and treatment outcomes in immune checkpoint therapies.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule)
    |
    CD8 expression • CD163 expression